5-(6-Aminopurin-9-yl)-4-chloro-2-(hydroxymethyl)oxolan-3-ol | 2627-62-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 5-(6-Aminopurin-9-yl)-4-chloro-2-(hydroxymethyl)oxolan-3-ol
• CAS: 2627-62-5
• 化学式: C₁₀H₁₂ClN₅O₃
• 分子量: 285.69
• InChiKey: ADXUXRNLBYKGOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• BIOCATALYTIC PRODUCTION OF NUCLEOSIDE ANALOGUES AS ACTIVE PHARMACEUTICAL INGREDIENTS
  申请人：PLASMIA BIOTECH, S.L.

  公开号：US20160076070A1

  公开（公告）日：2016-03-17

  A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.

  一种生物催化过程，用于生产活性药用成分（API）或其中间体，其中这些API或其中间体是式I的核苷类似物（NAs），并且所述的NAs作为药用抗病毒和抗癌药物具有活性，以及其中间体或前药。
• Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients
  申请人：PLASMIA BIOTECH, S.L.

  公开号：US10184142B2

  公开（公告）日：2019-01-22

  A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.

  一种生产活性药物成分 (API) 或其中间体的生物催化工艺，其中这些 API 或其中间体是式 I 的核苷类似物 (NA) 其中所述核苷类似物可作为药学上相关的抗病毒药物和抗癌药物、其中间体或原药。
• [EN] BIOCATALYTIC PRODUCTION OF NUCLEOSIDE ANALOGUES AS ACTIVE PHARMACEUTICAL INGREDIENTS<br/>[FR] PRODUCTION BIOCATALYTIQUE D'ANALOGUES NUCLÉOSIDIQUES EN TANT QUE PRINCIPES ACTIFS PHARMACEUTIQUES
  申请人：PLASMIA BIOTECH S L

  公开号：WO2014177585A2

  公开（公告）日：2014-11-06

  A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula (I), and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.